Arrhythmogenic Right Ventricular Cardiomyopathy — designated ARVC, also termed Arrhythmogenic Right Ventricular Dysplasia (ARVD) and increasingly broadened to Arrhythmogenic Cardiomyopathy (ACM) to encompass biventricular and left-dominant forms, a progressive heritable myocardial disease defined by fibro-fatty replacement of right ventricular myocardium producing structural right ventricular abnormalities, ventricular arrhythmias of right ventricular origin, and sudden cardiac death in young people and athletes, affecting an estimated 1 in 2,000–5,000 individuals with regional clusters of higher prevalence in the Veneto region of Italy (where population founder effect produces elevated disease frequency) and in Greece (particularly Naxos disease, the recessive syndromic form with palmoplantar keratoderma and woolly hair caused by plakoglobin JUP mutation) — caused in approximately 50–60% of genotype-positive patients by mutations in desmosomal protein genes encoding components of the intercalated disk that mediates mechanical coupling between adjacent cardiomyocytes: PKP2 encoding plakophilin-2 (the most commonly mutated gene, accounting for 25–40% of genotype-positive ARVC), DSP encoding desmoplakin (associated with left-dominant and biventricular forms and elevated risk of epicardial scar and sudden death), DSG2 encoding desmoglein-2, DSC2 encoding desmocollin-2, and JUP encoding plakoglobin, with additional non-desmosomal causes including TMEM43 (ARVD5, autosomal dominant Newfoundland mutation with near-complete penetrance and high mortality), PLN encoding phospholamban (associated with dilated cardiomyopathy and ARVC overlap), CDH2 encoding N-cadherin, and SCN5A mutations; the clinical phenotype progresses through a concealed phase of structural remodeling without symptoms, a symptomatic electrical phase with palpitations, presyncope, and exercise-triggered ventricular arrhythmias of left bundle branch block morphology (arising from diseased right ventricle) before right ventricular remodeling becomes apparent on imaging, a structural phase with right ventricular dilation and systolic dysfunction meeting imaging diagnostic criteria, and an advanced phase with biventricular failure and end-stage heart failure requiring transplantation; exercise is the most potent accelerant of ARVC progression — mechanical stress on diseased desmosomes during high-intensity exercise accelerates fibro-fatty replacement — making competitive athletics restriction a cornerstone of disease modification for affected patients and gene-positive family members; diagnosis follows the 2010 Task Force Criteria incorporating electrocardiographic abnormalities (epsilon waves in V1–V3, right precordial T-wave inversions beyond V1, premature ventricular complex morphology analysis), structural imaging criteria (right ventricular outflow tract dilation, right ventricular regional wall motion abnormalities on cardiac MRI with late gadolinium enhancement, echocardiographic criteria), tissue characterization (endomyocardial biopsy demonstration of fibro-fatty replacement, though sampling error limits sensitivity), arrhythmia criteria (sustained or non-sustained ventricular tachycardia of left bundle branch block morphology), signal-averaged electrocardiography (late potentials as a marker of slow conduction in fibro-fatty replaced myocardium), and family history and genetic testing criteria; management spans exercise restriction (cessation of competitive and high-intensity endurance sports, target <3 METs recreational activity for symptomatic patients), antiarrhythmic therapy (sotalol, flecainide, amiodarone), ICD implantation for high-risk patients (survivors of sustained ventricular tachycardia, patients with right ventricular dysfunction and arrhythmia burden), catheter ablation for ventricular tachycardia storm or recurrent ICD shocks, and transplantation evaluation for end-stage heart failure.
ARVC technology platforms — encompassing the genetic testing platforms where desmosomal gene panel sequencing and variant interpretation confirms molecular diagnosis, guides variant-specific exercise restriction enforcement, and enables family cascade screening to identify asymptomatic gene-positive relatives who require prophylactic exercise restriction before fibro-fatty replacement accumulates, the cardiology and electrophysiology platforms managing Holter surveillance, exercise stress testing, antiarrhythmic therapy titration, and ICD programming for ventricular tachycardia management, the cardiac imaging platforms acquiring and interpreting the cardiac MRI with late gadolinium enhancement and cardiac CT studies that characterize right ventricular structural remodeling and epicardial scar burden, the catheter ablation platforms managing complex epicardial and endocardial ventricular tachycardia substrate ablation procedures, the ICD remote monitoring platforms tracking arrhythmia burden and device integrity for high-risk ARVC patients, and the sports cardiology platforms documenting exercise restriction decisions and return-to-activity risk stratification — must maintain the availability and performance standards required by the exercise restriction enforcement imperative, arrhythmia surveillance obligations, ICD remote monitoring continuity, catheter ablation platform availability, and family cascade screening protocols that define modern ARVC management. This guide explains why ARVC tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the progressive cardiomyopathy surveillance, exercise restriction management, ICD remote monitoring, catheter ablation coordination, and family genetic screening that define modern care.
Why ARVC Care Tech Platforms Require Specialized Monitoring Attention
ARVC management is defined by several uniquely complex progressive cardiomyopathy challenges: the exercise restriction disease-modification imperative — exercise is the primary environmental modifier of ARVC penetrance and progression, and restriction from competitive athletics for gene-positive individuals — even those without current imaging criteria for diagnosis — is the most important preventive intervention available; the family cascade screening urgency — ARVC follows autosomal dominant inheritance in most forms, meaning first-degree relatives of probands carry a 50% prior probability of harboring the familial variant, and unidentified gene-positive relatives may be competing in endurance sports that accelerate their asymptomatic disease; the ventricular tachycardia storm management complexity — ARVC patients experience recurrent drug-refractory ventricular tachycardia storms requiring coordinated antiarrhythmic escalation, ICD shock management, and catheter ablation scheduling that demands integrated platform availability; and the progressive imaging surveillance obligation — serial cardiac MRI studies to track right ventricular outflow tract dimensions, late gadolinium enhancement burden, and biventricular function require reliable cardiac imaging platform availability over decades of surveillance.
Genetic testing platforms identify desmosomal mutations and drive family cascade screening. PKP2, DSP, DSG2, DSC2, JUP, TMEM43, PLN, and CDH2 sequencing with deletion/duplication analysis provides the molecular diagnosis that enables genotype-specific risk stratification and cascade testing of at-risk family members who may be exercising intensively without awareness of their disease risk. Monitor genetic testing platforms at 1-minute intervals during laboratory hours.
Cardiac MRI platforms characterize right ventricular structure and fibrofatty replacement. Late gadolinium enhancement cardiac MRI is the imaging standard for ARVC diagnosis, meeting Task Force Criteria for regional wall motion abnormalities and quantifying epicardial scar burden that predicts ablation substrate and sudden death risk. Monitor imaging platforms at 1-minute intervals during imaging hours.
ICD remote monitoring platforms detect ventricular tachycardia between clinic visits. ARVC patients with ICDs experience frequent appropriate shocks from recurrent ventricular tachycardia, requiring continuous remote monitoring for arrhythmia burden assessment, inappropriate shock detection, and device integrity surveillance. Monitor ICD remote monitoring platforms at 1-minute intervals, 24/7.
Electrophysiology and catheter ablation platforms manage ventricular tachycardia substrate. Complex epicardial and endocardial catheter ablation of ARVC ventricular tachycardia circuits in the fibro-fatty replaced right ventricular myocardium requires coordinated electroanatomic mapping and ablation scheduling platforms. Monitor catheter ablation platforms at 1-minute intervals during procedural hours.
What to Monitor on an ARVC Tech Platform
Genetic Testing — Desmosomal Gene Panel and Family Cascade Screening
Monitor genetic testing referral records (clinical suspicion documentation — right ventricular origin ventricular tachycardia, epsilon waves or right precordial T-wave inversions on ECG, signal-averaged ECG late potentials, cardiac MRI right ventricular abnormalities, family history of ARVC or sudden unexplained death in a young person, competitive athlete with palpitations or presyncope during exercise, Naxos disease phenotype with palmoplantar keratoderma and woolly hair), desmosomal gene panel sequencing records (comprehensive sequencing of PKP2, DSP, DSG2, DSC2, JUP and extended panel including TMEM43, PLN, CDH2, SCN5A — variant classification as pathogenic/likely pathogenic/VUS, deletion/duplication analysis by MLPA, genotype-phenotype guidance including DSP association with left-dominant phenotype and elevated sudden death risk, TMEM43 Newfoundland mutation nearly complete penetrance and high mortality risk documentation), family cascade genetic testing records (testing of first-degree relatives of index patients — parents, siblings, children — with genotype-positive result driving exercise restriction regardless of imaging findings, variant segregation analysis across family pedigree), genetic counseling records (exercise restriction counseling linked to genotype-positive result, variable penetrance and age-dependent imaging finding penetrance counseling, preconception genetic counseling, family communication strategy), and result delivery records at 1-minute intervals during laboratory hours. Alert immediately — ARVC gene panel platform failures during the evaluation of a 24-year-old marathon runner who presented with exertional ventricular tachycardia of left bundle branch block morphology delay the genotype assignment that would immediately remove this patient from marathon training — where continued high-intensity endurance training in a PKP2-positive individual is the single most powerful modifiable accelerant of fibro-fatty replacement and sudden death risk.
Cardiac MRI and Structural Imaging Surveillance
Monitor cardiac MRI ordering and scheduling records (surveillance MRI scheduling for gene-positive patients — annual or biennial frequency depending on symptom status and prior imaging findings; MRI technical adequacy assessment for ARVC evaluation — 1.5T or 3T, electrocardiographic gating quality, breath-hold technique), cardiac MRI interpretation records (right ventricular outflow tract diameter in systole and diastole, right ventricular volumes indexed to body surface area, right ventricular ejection fraction, regional wall motion abnormality documentation — right ventricular apical aneurysm, infundibular wall motion abnormality, subtricuspid dyskinesia constituting the triangle of dysplasia, late gadolinium enhancement pattern and location with particular attention to epicardial and transmural LGE in DSP-positive patients indicating elevated sudden death risk), cardiac CT records (alternative for patients with pacemakers or ICDs who cannot undergo MRI — right ventricular volumetry, wall motion assessment during contrast bolus, fatty infiltration assessment), echocardiography records (right ventricular dimensional assessment, tricuspid annular plane systolic excursion, right ventricular outflow tract fractional shortening, right ventricular regional wall motion abnormality screening, left ventricular systolic function for biventricular involvement surveillance), and Task Force Criteria diagnostic classification records (major versus minor criteria categorization, definite versus borderline versus possible ARVC diagnostic classification) at 1-minute intervals during imaging hours. Alert immediately — cardiac MRI platform failures during the surveillance study of a 28-year-old PKP2-positive patient who discontinued marathon training three years ago and whose most recent MRI two years prior showed mild right ventricular outflow tract dilation approaching the major Task Force Criterion threshold delay the current study that may cross the diagnostic threshold — changing management from exercise-restricted asymptomatic gene carrier to definite ARVC with arrhythmia risk stratification and ICD consideration.
Holter Monitoring and Ventricular Arrhythmia Surveillance
Monitor Holter monitor records (24-hour to 14-day continuous ambulatory cardiac monitoring for ventricular arrhythmia burden assessment — premature ventricular complex count and morphology including left bundle branch block morphology confirming right ventricular origin, non-sustained ventricular tachycardia detection, sustained ventricular tachycardia documentation, exercise correlation with arrhythmia burden in symptomatic patients), exercise stress test records (arrhythmia provocation during exercise in ARVC — exercise-induced ventricular tachycardia characteristic of ARVC confirming right ventricular origin; suppression of arrhythmia with exercise occasionally seen; post-exercise arrhythmia burden), signal-averaged ECG records (filtered QRS duration, low-amplitude signal duration, terminal RMS voltage — late potentials indicating slow conduction in fibro-fatty replaced myocardium meeting minor or major Task Force Criteria), loop recorder records (implantable loop recorder for syncope evaluation in suspected ARVC and for long-term arrhythmia burden surveillance in gene-positive patients declining ICD), and arrhythmia burden trend records (comparison of ventricular arrhythmia burden across serial Holter recordings to track disease progression) at 1-minute intervals during clinical hours. Alert immediately — Holter interpretation platform failures for a gene-positive patient whose post-exercise ventricular arrhythmia burden is being used to guide the ICD implantation shared decision-making conversation delay the arrhythmia documentation that anchors the risk stratification guiding one of the most consequential management decisions in ARVC care.
Antiarrhythmic Therapy Management
Monitor antiarrhythmic prescribing records (sotalol as first-line antiarrhythmic agent in ARVC with QTc monitoring — baseline QTc assessment, dose titration records, renal function adjustment for sotalol dose, in-hospital initiation with QTc monitoring for first doses; flecainide for premature ventricular complex suppression in structurally preserved right ventricular function; amiodarone for refractory ventricular tachycardia — thyroid, pulmonary, hepatic, and dermatological surveillance documentation), beta-blocker records (beta-blocker for ventricular tachycardia rate control and exercise-triggered arrhythmia suppression — carvedilol, metoprolol, bisoprolol dose titration), antiarrhythmic drug level records (amiodarone levels for toxicity management), antiarrhythmic adverse effect monitoring records (sotalol QTc prolongation requiring dose reduction or drug discontinuation, amiodarone thyroid dysfunction requiring endocrinology co-management, pulmonary toxicity requiring annual chest radiograph and pulmonary function testing), and drug interaction records (antiarrhythmic interactions with ICD programming — flecainide defibrillation threshold elevation requiring ICD programming adjustment) at 1-minute intervals during clinical hours.
ICD Implantation and Remote Monitoring
Monitor ICD implantation records (device selection for ARVC — transvenous ICD versus subcutaneous ICD assessment, S-ICD feasibility limited by frequent appropriate therapy need for ventricular tachycardia requiring anti-tachycardia pacing; dual-coil versus single-coil lead selection; epicardial patch assessment for high defibrillation threshold), remote monitoring transmission records (daily remote ICD transmissions in high-arrhythmia-burden ARVC patients — ventricular tachycardia electrograms, appropriate therapy delivery confirmation, anti-tachycardia pacing effectiveness documentation, inappropriate shock detection for T-wave oversensing or sinus tachycardia during exercise, battery and lead integrity trends), ventricular tachycardia storm records (multiple appropriate ICD therapies within 24 hours — emergency antiarrhythmic escalation documentation, deep sedation and anesthesia protocol for arrhythmia storm management, urgent catheter ablation scheduling triggers), and lead integrity records (right ventricular lead performance in the context of progressive fibro-fatty myocardial replacement at the lead tip — impedance trend monitoring, sensing threshold stability, pace threshold trends) at 1-minute intervals, 24/7 for remote monitoring platforms. Alert immediately — ICD remote monitoring platform failures that delay recognition of ventricular tachycardia storm in a 35-year-old with ARVC and a known high arrhythmia burden — who received seven appropriate ICD shocks between 11 PM and 2 AM — interrupt the electrophysiology team's emergency response escalating antiarrhythmic therapy to prevent refractory storm requiring emergency catheter ablation.
Catheter Ablation and Electrophysiology Study
Monitor electrophysiology study records (programmed ventricular stimulation for ARVC ventricular tachycardia inducibility assessment — VT morphology and cycle length documentation, substrate mapping under stimulation, non-inducibility after ablation confirmation), catheter ablation records (electroanatomic mapping of ARVC ventricular tachycardia substrate — CARTO or EnSite mapping system documentation; endocardial and epicardial substrate mapping; ablation lesion set documentation; procedural endpoint assessment — VT non-inducibility, scar homogenization), epicardial access records (pericardial access documentation for epicardial ARVC substrate mapping — particularly critical in DSP-positive patients with predominantly epicardial fibrosis; hemopericardium monitoring), and post-ablation surveillance records (ventricular tachycardia recurrence monitoring after ablation — early recurrence within 3 months versus delayed recurrence, ICD remote monitoring intensification post-ablation, repeat ablation candidacy assessment) at 1-minute intervals during procedural hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. ARVC management coordinates across genetics (molecular diagnosis, family cascade screening), electrophysiology (ventricular tachycardia management, ICD programming, catheter ablation), cardiac imaging (cardiac MRI, cardiac CT surveillance), sports medicine and sports cardiology (exercise restriction documentation), heart failure and transplant cardiology (end-stage ARVC management), and emergency medicine (ventricular tachycardia storm management) — authentication failures block every team member required to execute the imaging surveillance, arrhythmia management, ICD remote monitoring, and family cascade screening that define ARVC care.
SSL Certificates
Monitor SSL certificate expiry across all genetic testing platforms, cardiac MRI and imaging portals, ICD remote monitoring systems, electrophysiology platforms, catheter ablation coordination systems, and sports cardiology restriction documentation portals. Certificate errors disrupt ICD remote monitoring access (most critically), cardiac MRI scheduling, and genetic testing result delivery.
HIPAA and Hereditary Cardiomyopathy Privacy Considerations
ARVC technology platforms handle sensitive PHI including desmosomal gene panel molecular genetic testing with implications for patients, their children, and siblings (GINA protections for genetic information in health insurance and employment), lifetime cardiac MRI and arrhythmia records, ICD shock histories, competitive athletics restriction documentation affecting professional and collegiate athletic career eligibility, and family sudden cardiac death histories. The competitive athletics restriction imposed on genotype-positive ARVC patients and family members — which affects professional athletes and scholastic sports programs — creates documentation with implications beyond routine clinical PHI, requiring careful handling under HIPAA Privacy Rule protections against unauthorized disclosure.
Alerting Strategy for ARVC Care Tech Platforms
Immediate 24/7 alerting for ICD remote monitoring platforms: ARVC patients with ICDs experience ventricular tachycardia at all hours and frequently during night-time exercise recovery. There is no acceptable window of unavailability for ICD arrhythmia electrogram and therapy delivery transmission platforms.
Immediate clinical-hours alerting for cardiac MRI imaging platforms: Right ventricular structural surveillance and late gadolinium enhancement characterization for ARVC diagnosis and risk stratification.
Immediate laboratory-hours alerting for desmosomal genetic testing platforms: PKP2, DSP, DSG2, and full desmosomal panel sequencing cannot fail during evaluations where genotype-positive result drives immediate exercise restriction.
Immediate clinical-hours alerting for electrophysiology platforms: Holter interpretation, ventricular tachycardia management, antiarrhythmic titration, and catheter ablation coordination.
Sustained-failure alert (10–15 minutes): Sports cardiology restriction documentation, cardiac genetics counseling platforms, ARVC registry systems, and research coordination platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms ARVC platform availability from the geographies where ARVC specialty centers, desmosomal genetic testing laboratories, ICD clinics, cardiac MRI programs, and epicardial catheter ablation programs concentrate.
Status Page for ARVC Care Team Communication
A real-time status page gives electrophysiologists managing ventricular tachycardia storm responses, cardiac imagers interpreting ARVC Task Force Criteria on cardiac MRI, cardiac geneticists coordinating desmosomal cascade screening, sports cardiologists documenting exercise restriction eligibility, ICD clinic nurses reviewing daily remote transmissions, and heart failure physicians evaluating transplant candidacy immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in ARVC ventricular tachycardia storm protocols, ICD remote monitoring contingency procedures, and cardiac genetics cascade screening family notification workflows.
Vigilmon Setup for ARVC Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | ICD remote monitoring (VT electrograms and therapy) | 1 min | Slack + PagerDuty (24/7) | | Desmosomal gene panel sequencing (PKP2, DSP, DSG2, DSC2, JUP and extended) | 1 min | Slack + PagerDuty (lab hours) | | Family cascade genetic testing platform | 1 min | Slack + PagerDuty (lab hours) | | Cardiac MRI acquisition and interpretation | 1 min | Slack + PagerDuty (imaging hours) | | Holter monitor and arrhythmia surveillance | 1 min | Slack + PagerDuty (clinical hours) | | Exercise stress testing | 2 min | Slack + PagerDuty (clinical hours) | | Antiarrhythmic prescribing and monitoring (sotalol, amiodarone) | 1 min | Slack + PagerDuty (clinical hours) | | Catheter ablation procedural platform | 1 min | Slack + PagerDuty (procedural hours) | | Electroanatomic mapping system | 1 min | Slack + PagerDuty (procedural hours) | | Sports cardiology exercise restriction documentation | 2 min | Slack (business hours) | | ARVC patient registry and Task Force Criteria tracking | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure ICD remote monitoring platforms with immediate 24/7 alerting — this is the highest-priority platform in the ARVC care ecosystem
- Add desmosomal gene panel sequencing platforms with immediate laboratory-hours alerting
- Configure family cascade genetic testing platforms with immediate laboratory-hours alerting
- Add cardiac MRI acquisition and interpretation platforms with immediate imaging-hours alerting
- Configure Holter monitor and arrhythmia surveillance platforms with immediate clinical-hours alerting
- Add antiarrhythmic prescribing platforms with immediate clinical-hours alerting including QTc monitoring for sotalol initiation
- Configure catheter ablation procedural platforms with immediate procedural-hours alerting
- Add electroanatomic mapping system platforms with immediate procedural-hours alerting
- Configure exercise stress testing platforms with sustained-failure clinical-hours alerting
- Add sports cardiology restriction documentation platforms with sustained-failure business-hours alerting
- Configure ARVC patient registry with sustained-failure alerting during business hours
- Enable SSL certificate monitoring across all genetic testing, imaging, ICD monitoring, and electrophysiology platforms
- Add the status page URL to VT storm protocols, ICD contingency procedures, and cascade screening family notification workflows
Conclusion
ARVC technology platforms are embedded in clinical decisions where ICD remote monitoring platform availability when a 32-year-old competitive endurance cyclist with PKP2-positive ARVC — who was diagnosed six months earlier following a syncopal episode during a criterium race, had competitive cycling stopped immediately, and received an ICD for high-risk features including PKP2 pathogenic variant, right ventricular outflow tract enlargement meeting imaging major criterion, and non-sustained ventricular tachycardia on Holter — receives a series of appropriate ICD therapies at 8:45 PM while performing what the patient described as "a casual bike ride" that was in fact a 40-mile training ride at high intensity — when the remote monitoring platform must transmit the multiple ventricular tachycardia electrograms and four anti-tachycardia pacing therapy deliveries to the electrophysiology clinic whose on-call fellow must recognize the VT burden, assess whether the patient requires emergency evaluation, escalate antiarrhythmic therapy, and reinforce exercise restriction compliance with the counseling that this "casual ride" provided the hemodynamic stimulus that triggered the arrhythmia burden that may contribute to ongoing fibro-fatty replacement acceleration — cannot be disrupted by remote monitoring platform failures that leave the electrophysiology team unaware of the night's arrhythmia burden; where desmosomal genetic testing platform availability during the evaluation of a 19-year-old female collegiate soccer player whose 22-year-old brother — also a competitive athlete — died suddenly during a soccer match with subsequent genetic testing confirming PKP2 pathogenic variant cannot be disrupted by gene panel platform failures that delay the cascade test result that would identify the sibling as PKP2-positive before the next scheduled soccer match — where the period between family member's sudden death and gene result represents the interval of maximum exercise-related risk for this young woman who does not yet know whether she carries her brother's variant; and where cardiac MRI platform availability for the biennial surveillance scan of a 35-year-old PKP2-positive gene carrier who has been exercise restricted for three years and has had borderline imaging findings approaching the right ventricular major Task Force Criterion cannot be disrupted by cardiac MRI platform failures that delay the study which may cross the diagnostic threshold and change the patient's classification from possible ARVC to definite ARVC — triggering formal arrhythmia risk stratification, ICD shared decision-making, and intensified arrhythmia monitoring that are the clinical consequence of diagnostic threshold crossing in this progressive cardiomyopathy. An ICD remote monitoring platform unavailable when an ARVC patient's ventricular tachycardia storm begins at night, a desmosomal genetic testing platform unavailable when a young athlete's cascade test result is the difference between safe competition and sudden death, a cardiac MRI platform unavailable when progression past the diagnostic threshold changes the entire management algorithm — these are not IT incidents. They are clinical disruptions in the management of a progressive heritable cardiomyopathy where exercise-driven disease acceleration, ventricular tachycardia storm risk, and family transmission make platform reliability a direct determinant of sudden cardiac death prevention, disease modification, and family protection.
Uptime monitoring gives ARVC tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to ARVC specialty centers, desmosomal genetic testing laboratories, ICD clinics, cardiac MRI programs, epicardial catheter ablation programs, and compliance auditors that platform operational reliability matches the continuous arrhythmia surveillance intensity, progressive cardiomyopathy imaging precision, family cascade screening urgency, and ventricular tachycardia storm response speed of modern ARVC care.
Start monitoring your ARVC care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #ARVC #arrhythmogenic #cardiomyopathy #PKP2 #DSP #DSG2 #desmosomal #ICD #ventriculartachycardia #cardiacMRI #catheterablation #LGE #sotalol #channelopathy #suddencardiacdeath #electrophysiology #cardiacgenetics #exercise #rare #genetic #HIPAA #healthtech #digitalhealth #uptime #sre